Drug intelligence / Profile preview

meloxicam + cyclobenzaprine

Development stage
Discontinued
Lead developer
Eurofarma
Modality
Small Molecules
Administration
Oral
01

Overview

Meloxicam + cyclobenzaprine is a combination of two pharmaceutical agents: meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and cyclobenzaprine, a centrally acting skeletal muscle relaxant. Meloxicam works by inhibiting the enzyme cyclooxygenase 2 (COX-2), leading to decreased synthesis of prostaglandins that mediate pain and inflammation. Cyclobenzaprine acts on the central nervous system to reduce excessive muscle activity, thereby relieving muscle spasms and associated discomfort. This combination was developed for the treatment of back pain and other musculoskeletal conditions involving both inflammation and muscle spasm[3][6]. The fixed-dose product was developed by Eurofarma but its development appears to have been discontinued prior to market approval[6].

Other names
Meloxicam/cyclobenzaprineCyclobenzaprine/meloxicam
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on meloxicam + cyclobenzaprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on meloxicam + cyclobenzaprine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call